UNSPSC 51334503: Loxapine

This classification denotes an antipsychotic agent with the molecular formula C18H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LER583670J, chemically known as 1,4-butanedioic acid (succinic acid) but generally known as loxapine, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Loxapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08607MIG.

UNSPSC 51334503 Loxapine is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this designation shows minimal direct solicitation for loxapine itself. Instead, state and local bodies are using related pharmaceutical codes to procure broader drug inventories, emergency medical countermeasures, and prescription benefit program support. The actual work being solicited spans naloxone distribution systems, generic multi-source pharmaceutical supply agreements, and direct-to-manufacturer prescription programs. Issuing bodies range from county health departments (Seminole County, Florida) to state health and human services agencies (Texas HHS Commission) and multistate cooperative purchasing alliances (Minnesota MMCAP), reflecting the diverse organizational structures involved in public-sector pharmaceutical procurement. Most activity appears aimed at supporting community health initiatives, expanding access to opioid-overdose reversal agents, and managing pharmacy benefit costs across state employee and local government health plans.

Geographic activity centers on Florida and Minnesota, with Texas involvement in exploratory procurement strategy. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery, due July 26, 2023. Minnesota MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities including Oregon, with proposals due March 26, 2026; evaluation is weighted heavily on price competitiveness (75 percent), with mandatory compliance to current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, 3 percent administrative fee, and fixed or net-price contracting structures. Texas HHS issued RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for a direct-to-manufacturer prescription program serving self-insured state employee health plans. None of these opportunities explicitly target loxapine as a line item; procurement interest appears concentrated in broader pharmaceutical supply, emergency medical countermeasures, and pharmacy benefit program innovation rather than in the specific antipsychotic medication the code nominally represents.